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Historically, HIV transmission is preventable only by behavior change, if at all.  Because it is transmitted primarily through sex, prevention efforts have been focused on behavior changes like abstinence, minimizing number of partners, and condom use.  Those efforts have been effective, but there are still 2.5 million new infections worldwide each year. (WHO, 2011)  To further decrease the incidence of newly acquired HIV infection, attention has recently turned to biomedical prevention.  This area of research focuses on a new arsenal of prevention tools: vaccine development, pre- and post-exposure prophylaxis, and microbicides.  Vaccine development has not produced any efficacious results as of yet, while antiretroviral medications as prevention in the forms of both pills and microbicidal gels are promising.  The FDA recently approved Truvada, formerly used only as HIV treatment, as a pre-exposure prophylaxis drug.  Physicians can now prescribe it on-label to high-risk patients to reduce the likelihood of HIV transmission.  Microbicides may possibly be the most interesting and promising of the three types of biomedical prevention.  Although not a single one is approved for use in the general population, many clinical trials testing the efficacy of microbicides have been done and even more are currently underway or planned for the near future.  Microbicides have shown efficacy in some clinical trials evaluating them as a form of HIV prevention, but more research needs to be done to have conclusive evidence.  There is enough evidence to propose that microbicides could be an important part of HIV prevention science.  A major factor in both the 

developmental process of microbicides and testing their efficacy is the acceptability of their use among clinicians and the populations in which they will be used
1.1	IMPORTANCE TO PUBLIC HEALTH
There are 34.2 million people living with HIV worldwide. (WHO, 2011) According to the World Health Organization’s global health sector strategy on HIV/AIDS, women now account for 52% of the HIV prevalence worldwide. Microbicides were initially developed as a means for women to initiate prevention, as behavioral interventions traditionally involve a male condom.  The African epidemic always affected heterosexual men and women, but as more women in the United States were infected with HIV through sexual transmission (when it was previously mainly through intravenous drug use), a female-initiated prevention tool became more and more in demand. (Hoffman et al., 2010)  Vaginal microbicides were introduced as a prevention method that a woman could initiate if a man didn’t want to use a condom, and if necessary, could be used without her partner knowing.

In the United States, the largest incidence of new infections is in men who have sex with men (MSM).  In 2009, MSM made up 61% of new infections in the US.  They also account for 39% of all infections in the US.  (CDC, 2009) The disproportionate burden carried by this population creates a need for a microbicide that is safe when used in the rectum, and not just vaginally.  Development of a microbicide that is both rectally and vaginally safe is significant to public health as it impacts both homosexual and heterosexual populations.  Microbicides were originally formulated for safe use only in the vagina, and research on formulas also safe for anal is currently being done.

Although it is true that some of the increasing prevalence of people infected with HIV can be attributed to successful development of HIV and AIDS treatment, that is not the only reason so many people are living with HIV today.  A staggering 2.5 million new infections are detected each year, and that’s only the infections that are identified.  (WHO, 2011)  In the United States, an estimated one-fifth of those who are HIV positive do not know their HIV status, and are at risk to be actively spreading the virus to all sexual partners. (CDC, 2008)  It is true that more people living with the virus because of better treatment means that there are more people that can transmit the virus to others, but that should not be an inevitable situation.  Long before there were drugs to fight HIV, the mechanics of its transmission were known.  Behavioral interventions were developed, but the incidence of HIV each year shows that people do not abstain from sex, nor do they use a condom every time.  Sometimes they choose not to, but in many cases of rape or partner violence, there is not a choice to be made.  It is for these reasons that biomedical developments are an important part of prevention science.  Development of effective microbicide products, in combination with existing behavioral interventions and testing initiatives, could help to stop transmission of HIV worldwide.
1.2	METHODS









Table 1. Clinical Trials: Articles Reviewed
Author	Year	Description of Population	Sample Size	Type of Microbicide	Major Findings
Abdool Karim	2010	HIV-negative women ages 18-40,sexually active	1085	Tenofovir(antiretroviral)	Reduced HIV acquisition by 39% overall
Feldblum	2008	HIV negative women ages 18-35, multiple sex partners in last month	2153	SAVVY(surfactant)	No reduction of HIV incidence; no harmful treatment effect
Halpern	2008	HIV negative “high risk” women	1644	Cellulose sulfate(blocker)	Insufficient evidence of prevention; safe for use
McCormack	2010	HIV-negative women 18+ who are sexually active	9385	PRO2000(blocker)	Not efficacious for HIV prevention
Peterson	2007	HIV negative women ages 18-35, multiple sex partners in last month	2142	SAVVY(surfactant)	Insufficient evidence of prevention; more adverse reproductive events
Skoler-Karpoff	2008	HIV-negative women ages 16+, sexually active	6202	Carraguard(blocker)	No efficacy shown; safe for use
Van Damme	2002	HIV-negative female sex workers ages 18+	892	Nonoxynol-9(surfactant)	Enhances HIV-1 infection; no longer used

Microbicides are chemicals that are self-applied at either the vagina or rectum as a prophylactic agent.  They are intended to protect for receptive transmission, but they may also prevent forward transmission.  There are five categories of microbicides that have been tested so far: buffers, surfactants, blockers, antiretroviral agents, and co-receptor blockers. (Abdool Karim et al., 2012) Buffer agents lower the pH of the vagina to create an environment that is not ideal for viral transmission.  Surfactants inactivate pathogens by increasing the porosity of cell membranes.  Blockers prevent the entire virus from entering host cells.  Antiretroviral agents are commonly used as treatment for HIV/AIDS.  They work by preventing virus replication.  Co-receptor blockers prevent specific molecules in the virus from attaching to the surface of host cells.  (Abdool Karim et al. 2012)





In Van Damme et al.’s 2002 study, the participants chosen were female sex workers in four countries.  The drug being tested was nonoxynol-9, which was already proven as a spermicide.  The drug was formulated into a low-dose gel that was packaged in single-dose vaginal applicators and supplied to the women in the treatment arm of the study.  Condoms and safe sex counseling were supplied to both arms.  At the end of the study, the treatment arm had a slightly higher loss to follow-up than the control arm.  The study was stopped by the data safety monitoring board (DSMB) at the minimum number of seroconversions to perform statistical analysis, because the nonoxynol-9 group was showing a slightly increased risk of getting HIV.  This was related to lesions that the gel was causing.  Participants in the placebo group had lesions as well, but they did not develop as quickly in these participants as in the treatment group.  This could very well be a reason women were leaving the study.  Another concern of validity is inaccurate self-reporting of sex acts, which researchers had the women do by pointing to different pictures on a graphic chart.

Two trials were done testing the SAVVY (C31G) vaginal gel in Africa.  In 2007, Peterson et al.  did a study of high-risk HIV-negative women in Ghana.  Both the SAVVY (1.0% C31G) and placebo gels were clear gels in single-dose applicators.  This study was stopped early because not enough HIV infections were taking place in either group to significantly show the effectiveness of the trial drug.  That fact aside, participants reported use of their assigned gel only 75% of the time in the treatment group and 77% of the time in the control group.  Reasons for not using the gel were not directly addressed, but gel use did decrease over time in both groups of this study.  (Peterson et al., 2007)  Feldblum et al. did another trial with the same gel in 2008, this time among high-risk HIV-negative women in Nigeria.  Much like the trial in Ghana, this study used a 1.0% SAVVY gel as compared to a placebo gel, both of which were distributed to the women in single dose applicators.  Usage of the gel was reported at 78% in the SAVVY group and 79% in the placebo group.  Gel use among all participants also decreased over time in this study.  It was found during the study that large number of additional participants would need to be enrolled, so the DSMB watching this study also ended it prematurely. (Feldblum et al. 2008)  Both trials using SAVVY were unable to show effectiveness of the drug.  The barriers to statistically significant outcomes in both of these studies are similar: low adherence, unreliable self-reporting about sexual activity, consistent condom use by participants, and lower HIV incidence among the population studied than the researchers had expected.

Halpern et al. also published a paper in 2008 about the study that they did in Nigeria, this one testing the effectiveness of cellulose sulfate as HIV and STD prevention.  Instead of enrolling high-risk women like the other studies mentioned, to participate in this study, the women had to be HIV-negative, have an average of 3+ sex acts per week, and have multiple partners within the last month.  The methods of this study are much like that of the SAVVY trials:  all participants were provided with condoms, risk counseling, and a supply of single dose applicators of either cellulose sulfate or the placebo gel.  The reported use of gel in this study was 81%, slightly higher than in the SAVVY trials.  Like the other trials, the loss to follow-up was more than expected—almost 1/3 of each arm of the trial—leading to difficulties in showing the effectiveness of the drug tested.  This study was also stopped prematurely.  The researchers directly attributed their difficulties to “the challenges associated with performing clinical research among high risk women in poor settings.”  (Halpern et al., 2008)  

After the nonoxynol-9 and both SAVVY trials were stopped, another formulation called Carraguard was tested.  Skoler-Karpoff, et al.  also published the results of their study of this carrageenan-based compound in 2008.  This compound acts as a barrier between infected and non-infected cells, and was hoped to protect against HIV and other sexually transmitted diseases.  Women involved in this study were South African, age 16 or older, HIV-negative, and sexually active.   The inclusion criteria were not aimed at high-risk women, in fact, anyone who had sex one time in the past three months was eligible.  All women were given either the Carraguard or placebo gel in individual applicators, and instructed to apply it up to one hour before vaginal sex.  All participants were given condoms and counseling as part of the trial protocol.  Unlike previous trials, HIV incidence in this population was higher than the researchers had expected.  Even though other less inclusive studies tried to get the women at most risk, this shows that being more open with enrollment criteria may produce the incidence needed to show efficacy of a prevention method.  This study did not show efficacy in the Carraguard treatment, possibly due to low adherence.  However, Carraguard was tested in a trial a few years later and was the first vaginal microbicide that was shown to be efficacious against human papillomavirus (HPV). (Malais et al., 2011)  Carraguard was still shown to be a useful medication in preventing an STD, just not HIV.  

Even though this study did not show efficacy, it still had value in that it shows how important adherence is to a trial and how important it is to measure any variable in the study as objectively as possible.  A few things set this study apart from others when it comes to addressing low adherence and other difficulties.  Along with a self-report of usage, participants were instructed to return both used and unused gel applicators to the study staff, and these were counted and recorded as another measure of participant adherence. Self-reports of adherence by the participants were high, and “data from applicator testing differed substantially from self-reports of gel use.” (Skoler-Karpoff et al. 2008)  The researchers tested the applicators with a stain assay to see if they had been vaginally inserted, and used the number of applicators inserted divided by the average number of sex acts recorded from behavioral interviews to come up with a more accurate adherence estimate.  Using this estimate, the researchers found that on average participants were using the gel for only 42.1% of their sex acts—by far the lowest adherence of the vaginal microbicide trials.  The low level of adherence measured by stain assay as compared to the (much higher) level reported by participants could speak to the results of other studies as well.  Even if a medication works perfectly, effectiveness will never be seen if people are not using it.  This study showed us that more attention needs to be paid to both supporting and measuring participant adherence to protocol in microbicidal HIV prevention trials.

In 2010, McCormack et al. published another gel trial study that was done in South Africa, Tanzania, Zambia, and Uganda.  The net was cast wider in this study as well, as if a women was over 18, sexually active, HIV-negative, and willing to follow study protocol she was eligible if none of the exclusion criteria were met.  Exclusion criteria for this study are similar to other gel studies: pregnancy, regular spermicide use, and HIV-positive status are among the exclusion criteria.  Unlike other trials so far, this study tested two doses of the PRO2000 treatment gel (0.5% and 2.0%) against a placebo. Participants in this study were also instructed to return used and unused applicators as a measure of adherence.  Reported adherence for this study was 89%, which is high.  These researchers used a “triangulation method” for measuring adherence, which comprised of the self-reports, applicator counts, and the participants’ coital diaries.  All of these things suggested high adherence to gel use among participants, but in spite of that, PRO2000 gel was not found to be efficacious in preventing HIV transmission.  Like the other studies done so far, this one was stopped early because the treatment had little chance of ever showing significant reduction in HIV seroconversion.  However, the published paper emphasizes study strengths like strong social integration and community partnerships, which makes it stand out from previous trials.

Abdool Karim, et al. published the results of the CAPRISA trial in 2010.  The CAPRISA trial was innovative in that it was the first microbicide to use an antiretroviral medication in the gel formulation.  In this trial, tenofovir was used.  Tenofovir is an adenoside nucleotide that was already licensed for AIDS treatment in oral form, either alone (as Viread) or in a combination with other drugs in a single pill (Truvada and Atripla).  (De Clercq, 2007)  Because tenofovir had already been proven effective as AIDS treatment in humans and because it prevented HIV in macaques when it was administered subcutaneously, De Clercq asserted that it has the potential to be an effective prophylaxis in a microbicidal preparation for any route of HIV transmission—for example, a microbicidal gel for vaginal transmission or inoculation/subcutaneous administration for parenteral transmission, from something like sharing needles during intravenous drug use or a bloodborne pathogen exposure in a healthcare setting.  The CAPRISA trial followed a similar format as previous microbicide studies.  The tenofovir was formulated into a 1% gel, and South African women ages 18-40 who were HIV-negative and sexually active were recruited into the trial.  Adherence was measured in a manner similar to the PRO2000 trial.  Along with self reports, the women returned both used and unused applicators to the study staff.  Applicators not returned were assumed to be unused for study calculations.  This study had a “comprehensive adherence support program” based on each participant’s last month of usage history in addition to the instructions and counseling that were provided to all participants on an ongoing basis.  The retention rate in this study was extremely high, with 94.8% of the sample population remaining in the study until the endpoint.  However, adherence was lower than most of the other microbicide trials to date, at 72%, even with the addition of an individualized adherence support system. This could be attributed to the fact that an “adherent” sex act as it pertained to study protocol was strictly defined according to the dosage instructions, with the gel being used within the 12 hours before and the 12 hours after each sex act.  If the gel was used only once, that act would not be considered adherent.  In those who were considered “highly” adherent, the HIV incidence was 54% lower than in those who were not.  The study was carried out to completion and overall, the tenofovir gel in the study was estimated to reduce HIV incidence by 39%, arguably the most successful result of any microbicide trial to date.  

Even with this success, it is pointed out that at least 40% of the women in the study used the gel adherently less than half of the time, and in order for tenofovir or any HIV prevention to be effective, it must be used correctly and consistently.  This lack of adherence is in place even though the researchers went to great lengths to help participants achieve maximum adherence with the individualized adherence support system and counseling.  Acceptability of a microbicidal gel in the study was also very high, as “97.4% of the participants found the gel to be acceptable, and 97.9% indicated that they would use it if it prevented HIV.” (Abdool Karim et al., 2010)  Despite the high acceptability and support provided in the study, adherence didn’t reach the necessary levels for effective prevention.  The researchers stress the importance of continuing research to improve adherence, along with the combination of microbicidal gels with other HIV prevention methods.  They also stress the need for more effectiveness trials to be done.  Along with gathering more scientific evidence, more trials could improve adherence to HIV prophylaxis methods in general, as the gel was found to be more highly acceptable among participants in this trial once they know for sure that it prevents HIV.
Adherence

Acceptability is one of the major factors in the level of adherence to any therapy.  Many studies have been done to determine the level of acceptability of a topical microbicidal gel as an HIV prevention method.  The measure of acceptability of a microbicidal formulation includes physical properties like texture and scent, but also the likeliness of women to use a vaginal microbicide with their current partner(s).  (Morrow & Ruiz, 2008)  The best time to do acceptability research is early in the development of a microbicide—that way, a formulation that best suits the wants and needs of the population can be considered from the beginning.  (Morrow & Ruiz, 2008)   Women interviewed in qualitative studies agreed that having a woman-initiated form of prevention was important, saying that it gave women “responsibility to her own personal body” and that the gel had a role in “helping women…have control over the sexual acts that they…have to perform.” (Hoffman et al., 2010)  Another issue brought forth in qualitative interviews was the possibility of covert use.  Most women said that using a microbicide secretly with a casual or new partner would be possible, but those who were married or in long-term relationships would disclose use to their partners.  Women were uncomfortable with the idea of hiding microbicide use from a long-term partner, and many believed that a long-term partner would be able to tell that something was different during sex if a microbicide was being used. (Hoffman et al., 2010)  

Acceptability is not universal.  One issue that divides populations when it comes to acceptability of a formula is vaginal lubrication.  In many African cultures, women use vaginal drying agents to increase men’s sexual desire—a dry vaginal climate is preferred by many African men, and in a study of Depo Provera (a birth control method), South African Women reported vaginal wetness as an adverse effect.  (Smit et al., 2002)  This is just one example where populations are divided on an issue that affects acceptability of a microbicide product, and it is something that researchers need to consider when developing HIV prevention methods.  In order for a microbicide to be used consistently, it will need to be accepted in a society—and depending on the target population, microbicides will need to be formulated differently.  Increasing sexual pleasure and performance both for themselves and their partner is something that most women agree is integral to consistent microbicide use.  (Hoffman et al., 2010) However, sexual pleasure is not a one-size-fits-all concept, and in order to develop products that will be effective worldwide, researchers will need to take into account the sexual culture of multiple societies, and qualitative research is an important window into this issue.  Combined with data from participants in early phase clinical trials, it can help researchers to develop products than can achieve effective prevention as well as efficacy in a clinical trial.  

Acceptability is also a major issue in the development of microbicides that are safe for rectal use.  Issues impacting the acceptability of these products are similar to those impacting the development of vaginal microbicides, with lubrication being a concern for both insertive and receptive anal sex partners.  (Gross, 2001)  In a phase I clinical trial done at UCLA, participants tested a gel formulated for vaginal use in the rectum. The participants in this study responded that on average, they would be highly likely to use a microbicide any time they had receptive anal sex or any time they had sex without a condom.   The gel tested in this study also received high acceptability ratings on its physical properties like texture and smell. (Ventuneac et al., 2010)  Participants in the study did have some suggestions on how to make the product, but overall, comments were favorable.  The researchers state “the combined use of quantitative and qualitative assessment tools proved quite rich.  We were able to establish that although participants felt positive or neutral in their quantitative ratings of the application process and the applicator, when given the opportunity to elaborate, during the qualitative interviews, they pointed out a number of ways in [it] could be improved. This is useful information to take into account for the design…to anticipate (and correct) situations that may interfere with adherence not just in Phase 1 clinical trials but also in larger Phase 2 or 3 trials.” (Ventuneac et al., 2010)





Although research on rectal microbicides is not quite as far along as the research being done in vaginal formulations, there are many studies currently underway.  The following table outlines the work in rectal microbicide development currently being done by the Microbicide Trial Network (MTN, 2012). 

Table 2. Ongoing Microbicide Research
Protocol Number	Study Name	Study Status
MTN-007	A Phase 1 Randomized, Double-Blinded, Placebo-Controlled Rectal Safety and Acceptability Study of Tenofovir 1% Gel	Closed to Follow-Up
MTN-012/IPM 010	Male Tolerance Study of Dapivirine Gel Following Multiple Topical Penile Exposures	Closed to Follow-Up
MTN-014	A Phase 1 Crossover Trial Evaluating the Pharmacokinetics of Tenofovir Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments In Women	Pending
MTN-017	A Phase 2 Randomized Sequence Open Label Expanded Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel.	Pending

These studies are all using antiretroviral medications, which showed high efficacy in the CAPRISA trial.  The results of the CAPRISA trial in combination with the high lubricant use of many MSM provide the basis for the great excitement of many scientists about the potential that rectal microbicides have for HIV prevention.  Rectal microbicide groups like the International Rectal Microbicide Advocates (IRMA) work hard to develop new studies and educate the community about what’s going on in the research world. (McGowan, 2011)  A grant program called “Be the Generation Bridge,” funded by the National Institute of Allergy and Infectious Diseases, helps community organizations that already provide HIV testing and AIDS case management services to create and then integrate education materials about biomedical prevention like vaccine development, pre- and post-exposure prophylaxis, and microbicides into their existing programs.  (NIH, 2012)  These educational programs all exist in cities where there is a site doing biomedical prevention research. Programs and advocacy groups can help the development of microbicides and other biomedical prevention by educating the scientific and lay communities about the ongoing research.
1.4	DISCUSSION
Throughout the past decade of microbicide research, we have learned that many things don’t work and that some things do.  The early vaginal microbicide trials with spermicides and other compounds were discouraging, and for a while nothing seemed to be preventing transmission.  It was unclear if the compounds being tested were actually ineffective, or if the major issue was a lack of adherence by study participants.  Throughout this inquiry, qualitative and quantitative studies were done, and great insight into participant adherence and how to increase it was gained.  The CAPRISA trial changed everything.  Using tenofovir, an antiretroviral medication, proved efficacious in preventing HIV transmission in a vaginal microbicide trial. (Abdool Karim et al., 2010)  Since then, a large quantity of research has been done in a relatively short time to move both vaginal and rectal microbicide options further towards US Food and Drug Administration (FDA) approval and widespread use by populations at high risk of contracting HIV.  Now that a more efficacious product is available, it is more important than ever to understand all the factors that affect adherence, since it is still a possible barrier to achieving positive results in a clinical trial.  More studies should be done to find out exactly what affects adherence during a microbicide trial, and what we can do to maximize adherence level in future studies.  

Another reason HIV prevention research is slow to produce results is that it is clearly unethical to have high-risk participants engage in completely unprotected sex, so participants in treatment and placebo arms of all HIV prevention receive standard care, usually consisting of a condom supply and safe sex counseling.  These things, when used correctly and consistently, are effective at preventing HIV transmission—so incidence in trials has frequently been lower than researchers needed to see to prove statistically significant efficacy of their trial method.  Multiple clinical trials testing microbicide efficacy have been stopped for this reason, and even in trials that continued to their endpoint, it is important to look closely at the results for any differences in the condoms and counseling provided to the different arms of the study.  Any bias could alter the results, and it is integral to have everything in a study except the microbicide formula be as close to the same as possible in order to see the true effect of the drug.

For this reason, more research is needed in the development of both vaginal and rectal microbicides.  Now that efficacious combinations of medication have been discovered, larger effect sizes can be seen once bigger trials are underway.  Research in lesbian, gay, bisexual, and transgender (LGBT) healthcare disparities can inform the development of microbicides and other biomedical prevention by helping clinicians make their practice as accommodating, and therefore attractive, to high-risk populations as possible.  Acceptability research has informed development by suggesting that if a product is similar to a lubricant that is already used for sex, high-risk populations, especially MSM, would be more likely to use the product as HIV prevention.  Physical properties of the microbicide need to be attractive to the population for which its use is intended, and although some qualitative research has been done around this idea, more studies are needed to develop a product that is desirable by populations worldwide.  A form of prevention that people are excited to use would be an incredible asset for those working in the field of HIV prevention and all populations that can potentially benefit from such a product.

Education in the community needs to be ongoing.  HIV is a worldwide epidemic that biomedical prevention can help us end forever, but there is still a huge stigma surrounding sex, and in order for these prevention methods to be effective we all need to be vigilant in our work to get rid of this stigma.  Prevention research is a lengthy process that requires participation from everyone—without interested and engaged community partners, recruitment efforts will not be successful.  Community-based organizations, advocacy groups, and individuals can all work together to help the cause.  Community involvement is essential to advance the research process.  Biomedical research is just one piece of the puzzle that is HIV prevention.  Further research in biomedical prevention, especially in microbicide development, should be done   in order to move development toward an easily accessible prevention method forward.  Combining research on adherence, acceptability, and microbicide efficacy will result in a huge step forward for the field of HIV prevention and possibly a new way to stop transmission of the HIV virus forever.
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